Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, announced new preliminary end-of-treatment (EOT) data from the Phase 2a clinical trial (IM-PROVE II, A ...

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy All six patients have seroconverted and have high titers ...

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy All six patients have seroconverted and have high titers ...

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy. T ...

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy. T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or O ...

财务数据和关键指标变化 - 公司2024年第一季度现金、现金等价物和投资总额约为1.38亿美元,较2023年12月31日的1.32亿美元有所增加 [24] - 公司预计2024年全年现金净流出将在6300万美元至6700万美元之间,不包括ATM计划的任何收益 [24] - 公司认为目前的现金储备足以为其运营提供资金支持,预计可维持至2026年第二季度 [25] 各条业务线数据和关键指标变化 - 公司正在开展三项针对慢性乙型肝炎的Phase 2a临床试验,分别评估imdusiran联合干扰素、imdusiran联合VTP-300疫苗以及imdusiran联合durvalumab的疗效 [13][16][18] - 公司正在推进自主研发的口服小分子PD-L1检查点抑制剂AB-101的临床开发,目前正在进行第1a/1b期临床试验,评估其安全性、耐受性、药代动力学和药效学 [20][21][22] 各个市场数据和关键指标变化 - 未提及 公司战略和发展方向及行业竞争 - 公司致力于开发能够实现慢性乙型肝炎患者功能性治愈的疗法,包括通过降低表面抗原、抑制乙肝病毒DNA和增强免疫系统三管齐下的方法 [12] - 公司认为imdusiran和AB-101有望成为实现这一目标的关键资产 [12] - 公司正在通过多项临床试验评估imdusiran联合不同免疫调节剂的疗效,以期找到最佳的组合疗法 [13][16][18] - 公司将继续保护和捍卫其知识产权,包括脂质纳米颗粒递送技术 [27][28][29] 管理层对经营环境和未来前景的评论 - 公司对imdusiran和AB-101在治疗慢性乙型肝炎方面的潜力表示乐观 [12] - 公司认为2024年上半年已完成大部分关键里程碑,包括报告AB-101 Phase 1a/1b临床试验的初步数据,以及启动imdusiran联合durvalumab的Phase 2a临床试验 [26] - 公司表示下半年将报告imdusiran联合nivolumab的初步数据,以及AB-101多剂量递增试验的初步数据 [26] 问答环节重要的提问和回答 问题1 **Dennis Ding 提问** - 公司何时可能获得功能性治愈的信号数据 [31][32] - 公司何时可能启动下一阶段的临床试验 [31][32][33][34] **Mike McElhaugh 和 Karen Sims 回答** - 功能性治愈信号需要在停止所有治疗6个月后才能评估,公司会在有足够数据时公布 [34][35] - 公司会根据现有临床试验的数据情况决定下一步的临床开发计划,不需要等待所有试验完成 [35] 问题2 **Thomas Yip 提问** - 下一个imdusiran的临床试验是否会单药或联合用药评估 [37][38] - durvalumab在AB-729-203试验中不同给药时间点的设计考虑 [39][40][41] **Karen Sims 回答** - 公司认为需要联合用药才能实现慢性乙肝的功能性治愈 [38] - 设计不同durvalumab给药时间点是为了探索在imdusiran降低表面抗原过程中,最佳的免疫调节时机 [40][41] 问题3 **Unidentified Analyst 提问** - AB-101的最高剂量是否为25mg [45][46][47] - AB-729-202试验中nivolumab联合数据是否影响了AB-729-203试验的设计 [45][47] - 公司对ALPK1激动剂的看法 [45][50] **Karen Sims 和 Mike Sofia 回答** - 25mg只是目前测试的最高剂量,未来可能会调整 [46][47] - 无法评论AB-729-202试验中nivolumab联合数据,将在下半年公布 [47] - 公司正在关注ALPK1激动剂的相关数据,但尚未形成明确看法 [50]

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Arbutus, which belongs to th ...

EXHIBIT 99.1 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court da ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arbutus Biopharma (ABUS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Arbutus Biopharma is one of 1051 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different gro ...